When it comes to pharmaceuticals, there’s plenty of talent and expertise in the Greek industry and Pharma-Data proves it. Since it was founded, in 2005, the company has risen to the top of the domestic market and established business partnerships with some of the biggest names in the field, worldwide.
Beginning to End
Specializing in new pharmaceutical products, especially generics, Pharma-Data S.A. covers all aspects of product development—from researching and sourcing APIs and developing manufacturing processes to stability testing and dossier writing—and offers a comprehensive range of regulatory affairs services, as well as business development and licensing solutions. To date, the company is responsible for over 140 marketing authorizations of pharmaceutical products.
Excellence at Home, Recognition Abroad
Pharma-Data is well established in the Greek market and works with all domestic pharmaceutical companies, helping them sell their products abroad and acquire dossiers and know-how from foreign organizations. Beyond the borders, the company also participates in international projects and has a number of long-term agreements with some of the largest multinationals in the business.
Never Mind the Blockbusters
In a world of multinational pharmaceutical corporations, Pharma-Data uses its small size to its advantage. Instead of trying to compete with the industry’s heavyweights over blockbuster drugs, the company turned its attention to niche areas where competition is scarce. In doing so, Pharma-Data is strategically positioned as an excellent option for larger organizations that want to outsource product development of niche drugs.
Number of Employees
Markets Where Pharma-Data S.A. Is Active
Greece, South Africa, Asia, Europe, Middle East, North & South America
Why Pharma-Data S.A. is Successful
As a small organization, Pharma-Data is flexible and able to avoid time-consuming internal bureaucracy and unnecessary expenses. As a result, the company can meet customer needs in a timely fashion and to the highest European standards, whilst keeping costs much lower than its European competitors.
The Innovative Edge
In developing new pharmaceutical products, Pharma-Data innovates on a daily basis. Beyond the usual generic pharmaceuticals, however, the company also designs new pharmaceutical forms of existing drugs and researches and proposes new, more effective combinations. From Pharma-Data’s point of view, pushing the envelope is the only way that a small company like itself can survive international competition.
Despite the unstable business environment in Greece, Pharma-Data overcame difficulties by investing in human resources and new projects. Resisting temptation to move operations abroad, the company focused its efforts on establishing new collaborations and successfully maintained its growth trajectory.
Goals for 2013
In 2013, Pharma-Data plans to establish its own, independent laboratory for galenic and analytical development. Through this, the company wishes to secure FDA approval—in addition to EU-GMP approval, which it already has—and open the doors for more projects in the United States in the coming years. (Pharma-Data is one of the few companies which is ISO certified for R&D services and new product development.)
Pharma-Data S.A. Is Currently Looking For
Pharma-Data S.A.’s Patents
To date, the company has submitted the following patent applications, either as sponsor or as Invention Participant:
- Aqueous Acetaminophen Compositions and Method of Preparation; EP09172801
- Method for the Preparation of Levothyroxine Compositions; PCT/IB2011/051015
- Pharmaceutical Dosage Forms of Iron (II) (or Ferous) Gluconate and Method of their Preparation; GR20110100377
- Stable Pharmaceutical Aqueous Solutions of Antipsychotic Drugs; GR1006327